Taiwanese biopharmaceutical company Golden Biotechnology Corp. on Wednesday released positive interim unblinded data from the Phase 2 clinical trial of its oral investigational new drug for COVID-19 Antroquinonol, and announced it plans to apply for Emergency Use Authorization (EUA) in the United States in April.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Society
Migrant fishers' rights deal takes force after over 1 year in limbo
04/20/2024 06:34 PM - Politics
- Politics
President-elect Lai's commitment to status quo welcomed: AIT chair
04/20/2024 05:56 PM - Culture
Nymphia Wind makes history by triumphing on RuPaul's Drag Race
04/20/2024 03:18 PM - Sports
Taiwan's gymnast Lee Chih-kai 'burnt out' after hope for Paris dims
04/20/2024 03:05 PM